Publications by authors named "Orsi Giulia"

Claim this Profile
P
Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial.
Michele Reni, Marina Macchini, Giulia Orsi, Letizia Procaccio, Giuseppe Malleo

Lancet· December 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients.
Ruggero Ponz de Leon Pisani, Livia Archibugi, Pilar Lazzano, Niccolò Bina, Giuseppe Vanella, Giulia Orsi

Dig Liver Dis· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endoscopic ultrasound-guided choledochoduodenostomy versus hepaticogastrostomy combined with gastroenterostomy in malignant double obstruction (CABRIOLET_Pro): A prospective comparative study.
Giuseppe Vanella, Roberto Leone, Francesco Frigo, Michiel Bronswijk, Roy L J van Wanrooij, Giulia Orsi

DEN Open· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants.
Michele Milella, Giulia Orsi, Mariacristina di Marco, Lisa Salvatore, Letizia Procaccio

Cancer Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life.
Michele Reni, Guido Giordano, Marco Audisio, Giulia Orsi, Marina Macchini

Dig Liver Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma.
Daniel Oyon, Amaya Lopez-Pascual, Borja Castello-Uribe, Iker Uriarte, Giulia Orsi

J Exp Clin Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell Membrane Fatty Acids and PIPs Modulate the Etiology of Pancreatic Cancer by Regulating AKT.
Carolina Torres, Georgina Mancinelli, Jee-Wei Emily Chen, Jose Cordoba-Chacon, Danielle Pins, Giulia Orsi

Nutrients· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence.
Domenico Tamburrino, Claudia Arcangeli, Federico De Stefano, Giulio Belfiori, Marina Macchini, Giulia Orsi

Surgery· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants.
Catia Carconi, Carlo Bosi, Mario Scartozzi, Massimiliano Cergnul, Marika Cinausero, Giulia Orsi

Pancreatology· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients.
Giulia Orsi, Catia Carconi, Paola Ghiorzo, Paola Carrera, Lorenza Pastorino

Eur J Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isolated lung metastases from pancreatic ductal adenocarcinoma (PDAC): Diagnostic and therapeutic challenges of a different disease.
Orsi Giulia, Bandiera Alessandro, Carretta Angelo, Migliori Paolo, Chavez Rosa, Veronesi Giulia

Semin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma.
Paolo Passoni, Michele Reni, Sara Broggi, Najla Slim, Andrei Fodor, Giulia Orsi

Clin Transl Radiat Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma.
Michele Reni, Umberto Peretti, Marina Macchini, Giulia Orsi, Annamaria Militello

Dig Liver Dis· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy.
Marina Macchini, Giulio Belfiori, Stefano Crippa, Giulia Orsi, Giulia Gasparini

Dig Liver Dis· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology.
Caterina Vivaldi, Virginia Genovesi, Clara Ugolini, Laura Bernardini, Andrea Casadei-Gardini, Giulia Orsi

Oncology· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Neoadjuvant FOLFIRINOX in Borderline Resectable Pancreatic Cancer: A Network Meta-Analysis.
Fausto Petrelli, Michele Ghidini, Marina Macchini, Giulia Orsi, Umberto Peretti

J Gastrointest Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma.
Giulia Gasparini, Francesca Aleotti, Marco Palucci, Giulio Belfiori, Domenico Tamburrino, Giulia Orsi

Dig Liver Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes.
Anna Maria Militello, Giulia Orsi, Alessandro Cavaliere, Monica Niger, Antonio Avallone

Cancer Chemother Pharmacol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples.
Miriam Redegalli, Greta Grassini, Gilda Magliacane, Lorenza Pecciarini, Marco Schiavo Lena, Giulia Orsi, Maria Giulia Cangi

Clin Gastroenterol Hepatol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EUS-guided gastroenterostomy for management of malignant gastric outlet obstruction: a prospective cohort study with matched comparison with enteral stenting.
Giuseppe Vanella, Giuseppe Dell'Anna, Gabriele Capurso, Patrick Maisonneuve, Michiel Bronswijk, Giulia Orsi

Gastrointest Endosc· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv).
Giulia Orsi, Alessandro Cavaliere, Giampaolo Tortora, Sara Lonardi, Marina Macchini

Br J Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lessons and open questions in borderline resectable pancreatic cancer.
Michele Reni, Giulia Orsi

Lancet Gastroenterol Hepatol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is the Delphi's Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma?
Michele Reni, Marina Macchini, Giulia Orsi

JAMA Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pancreatic cancer: still a cold case?
Michele Reni, Giulia Orsi

Lancet Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients.
Marina Macchini, Federico Centonze, Umberto Peretti, Giulia Orsi, Anna Maria Militello

Cancer Treat Rev· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis